Travere Therapeutics, Inc. (TVTX) SEC Filings & Earnings Calls

CEO transition could signal strategic shift or internal challenges; no context provided.

“CEO separation and new CEO appointment with no explanation of reasons.”

Dependence on FILSPARI for revenue growth

“Net product sales $ 161,352 $ 94,842 $ 285,844 $ 170,702” · word for word

High SG&A growth outpacing revenue growth

“Selling, general and administrative 96,112 62,581 176,366 122,995” · word for word

Inducement expense and debt conversion dilution

“Inducement expense ( 40,008 ) — ( 40,008 ) —” · word for word

Net loss widened significantly due to increased R&D, SG&A, and $40M inducement expense from convertible note repurchases.

“Net loss for the second quarter of 2026 was $34.8 million, compared to $12.8 million” · word for word

SG&A expenses increased 53.5% due to commercial investments for FSGS launch and IgAN commercialization.

“SG&A expenses were $96.1 million, compared to $62.6 million”

Potential for transition disruption if successor not fully prepared, but appears low risk given planned timeline.

“Company expects orderly transition; successor has been with company since 2021 and has relevant experience.”

Potential for disruption in research leadership, but mitigated by planned transition and internal successor.

“Company expects orderly transition; successor is current CMO with expanded role.”

Significant financial commitments with upfront and milestone payments; development and regulatory risks.

“Upfront $112.5M, up to $1.03B in milestones; development cost sharing; no guarantee of approval.”

Potential dilution from future equity grants under the amended plan.

“Approval of additional 3M shares for equity incentive plan.”

Increased leverage and potential dilution; interest payments and conversion features may pressure equity.

“Notes are senior unsecured obligations; conversion may dilute shareholders; interest rate 0.50%.”

Dependence on FILSPARI for revenue; pipeline risk for pegtibatinase.

“Revenue concentrated in FILSPARI; pegtibatinase Phase 3 topline data not expected until 2H 2027.”

Dependence on FILSPARI for revenue growth

“Our future prospects are highly dependent upon our ability to successfully develop and execute commercialization strategies for our products, including FILSPARI, and to attain market acceptance among physicians, patients and healthcare payers.” · word for word

Generic competition for tiopronin products

“We face substantial generic and other competition, and our operating results will suffer if we fail to compete effectively.” · word for word

Clinical trial and regulatory risk for pegtibatinase

“Our clinical trials are expensive and time-consuming and may fail to demonstrate the safety and efficacy of our product candidates.” · word for word

Commercial launch execution risk for FILSPARI in FSGS indication.

“Risks and uncertainties related to the Company's planned commercial launch of FILSPARI in FSGS.” · word for word

Competition from other therapies for FSGS may emerge.

“FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, but future competition is possible.” · word for word

FSGS sNDA Approval Delay/Risk

“In January 2026, we announced that the FDA extended the review timeline for the sNDA, and the new PDUFA target action date is April 13, 2026.” · word for word

Manufacturing Scale-Up Risk for Pegtibatinase

“The voluntary enrollment pause enabled us to address necessary process improvements in manufacturing scale-up to support initial commercial scale manufacturing as well as full enrollment in the HARMONY Study.” · word for word

Dependence on FILSPARI for revenue; FSGS approval not yet granted.

“PDUFA target action date for FILSPARI in FSGS is April 13, 2026.” · word for word

SG&A expenses increased significantly due to launch preparations.

“SG&A expenses for the fourth quarter of 2025 were $101.7 million, compared to $69.5 million for the same period in 2024.” · word for word

Regulatory delay for FILSPARI in FSGS; approval not guaranteed

“FDA extended review; no guarantee of approval”

Regulatory risk for FILSPARI sNDA in FSGS with PDUFA on Jan 13, 2026; FDA additional information requests may delay or deny approval.

“The Company recently received additional information requests from the FDA to further characterize the clinical benefit of FILSPARI” · word for word

Dependence on FILSPARI for revenue; FSGS approval and launch are key catalysts.

“Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26” · word for word

SG&A expenses increased significantly due to FSGS launch preparation and commercialization investment.

“SG&A expenses $86.5M vs $65.6M; difference is largely attributable to investment in preparations for a potential FSGS launch in January 2026”

Pegtibatinase Manufacturing Scale-up Risk

“The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study.” · word for word

FSGS sNDA Regulatory Risk

“The sNDA remains under review by the FDA with a PDUFA target action date of January 13, 2026.” · word for word

Competition Risk

“We face substantial generic and other competition, and our operating results will suffer if we fail to compete effectively.” · word for word